

TABLE OF CONTENT

1. BASIC INFORMATION	3
2. HAZARDS IDENTIFIED	4
3. SUMMARY OF ASSESSMENT PROCESS (CALCULATION OF ADE VALUE)	5
4. IDENTITY OF THE ACTIVE SUBSTANCE	7
5. OBJECTIVE AND SEARCH STRATEGY	8
6. INTRODUCTION	8
7. HAZARD IDENTIFICATION	9
a. Pharmacodynamics data	9
b. Acute toxicity	9
c. Repeated dose toxicity	12
d. Carcinogenicity	13
e. <i>In vitro</i> / <i>in vivo</i> genotoxicity studies	13
f. Reproductive and developmental toxicity	14
8. IDENTIFICATION OF CRITICAL EFFECTS	15
a. Most sensitive indicator of an adverse effect seen in non-clinical toxicity data	15
b. Clinical therapeutic and adverse effects	15
9. RATIONALE FOR NOAEL VALUES SELECTION	17
10. APPLICATION OF ADJUSTMENT FACTORS (rationale for the adjustment factors)	18
a. UF _A : Interspecies differences	18
b. UF _H : Inter-individual differences	19
c. UF _S : Subchronic-to-chronic extrapolation (duration of exposure)	19
d. UFL: LOAEL-to-NOAEL extrapolation	19
e. UF _D : Database completeness	20
11. MODIFYING FACTOR (MF)	20
12. PK CORRECTION	20
13. ADE CALCULATION	20
14. REFERENCES	22
ANNEX 1: PHARMACOKINETICS AND METABOLISM	24
ANNEX 2: GLOSSARY	25
ANNEX 3. SUMMARY OF THE EXPERT CV	26

The report is valid for 3 (three) years as of the date of the assessment review data.

Reproduction or unauthorized distribution is strictly prohibited. The present document is provided to a single organization and may not be resold, copied, or redistributed to other companies. The use by any company other than the one indicated in the watermark is prohibited.